Kymera Common Stock Shares Outstanding vs Current Deferred Revenue Analysis

KYMR Stock

USD 47.02 2.04 4.54%

Kymera Therapeutics financial indicator trend analysis is infinitely more than just investigating Kymera Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kymera Therapeutics is a good investment. Please check the relationship between Kymera Therapeutics Common Stock Shares Outstanding and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

Common Stock Shares Outstanding vs Current Deferred Revenue

Common Stock Shares Outstanding vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kymera Therapeutics Common Stock Shares Outstanding account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak relationship.

The correlation between Kymera Therapeutics' Common Stock Shares Outstanding and Current Deferred Revenue is 0.34. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Kymera Therapeutics, assuming nothing else is changed. The correlation between historical values of Kymera Therapeutics' Common Stock Shares Outstanding and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Kymera Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Common Stock Shares Outstanding i.e., Kymera Therapeutics' Common Stock Shares Outstanding and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.34

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Kymera Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.At this time, Kymera Therapeutics' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 11/25/2024, Enterprise Value is likely to grow to about 1.9 B, while Selling General Administrative is likely to drop slightly above 30.3 M.

	2021	2022	2023	2024 (projected)
Interest Expense	175K	176K	196K	132.7K
Depreciation And Amortization	2.4M	3.0M	3.6M	2.3M

Interest Expense Depreciation And Amortization

Kymera Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.66	0.94	0.94	0.99	0.81	0.95	0.57	0.79	0.5	-0.84	0.88	0.54	0.74	-0.57	0.89	0.98	0.55	0.78	-0.2	0.66	0.96	0.96	0.72	0.99	0.67
Short Long Term Debt Total	0.66		0.74	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13	1.0	0.73	0.68	0.69	0.6	1.0
Other Current Liab	0.94	0.74		0.81	0.94	0.61	0.94	0.68	0.54	0.31	-0.92	0.92	0.76	0.65	-0.56	0.95	0.88	0.66	0.92	-0.15	0.74	0.99	0.97	0.63	0.94	0.76
Total Current Liabilities	0.94	0.64	0.81		0.89	0.94	0.87	0.55	0.91	0.65	-0.72	0.85	0.43	0.82	-0.38	0.76	0.93	0.5	0.65	-0.02	0.64	0.85	0.83	0.86	0.89	0.64
Total Stockholder Equity	0.99	0.6	0.94	0.89		0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.98	0.59	1.0	0.62
Other Liab	0.81	0.54	0.61	0.94	0.72		0.7	0.44	0.96	0.64	-0.56	0.74	0.29	0.83	-0.2	0.56	0.82	0.38	0.47	0.18	0.54	0.66	0.64	0.91	0.72	0.52
Net Tangible Assets	0.95	0.8	0.94	0.87	0.95	0.7		0.74	0.68	0.53	-0.94	0.89	0.6	0.79	-0.46	0.96	0.92	0.74	0.79	-0.28	0.8	0.96	0.96	0.64	0.95	0.82
Property Plant And Equipment Net	0.57	0.99	0.68	0.55	0.52	0.44	0.74		0.28	0.43	-0.88	0.8	0.79	0.79	0.14	0.8	0.46	0.99	0.68	0.14	0.99	0.66	0.61	0.62	0.52	0.99
Current Deferred Revenue	0.79	0.38	0.54	0.91	0.74	0.96	0.68	0.28		0.69	-0.46	0.61	0.07	0.74	-0.31	0.5	0.84	0.25	0.34	-0.06	0.38	0.62	0.63	0.76	0.74	0.37
Net Debt	0.5	0.47	0.31	0.65	0.46	0.64	0.53	0.43	0.69		-0.38	0.51	0.0	0.78	0.23	0.32	0.47	0.47	0.01	-0.18	0.47	0.42	0.44	0.49	0.46	0.46
Retained Earnings	-0.84	-0.91	-0.92	-0.72	-0.83	-0.56	-0.94	-0.88	-0.46	-0.38		-0.9	-0.79	-0.77	0.32	-0.97	-0.76	-0.88	-0.85	0.13	-0.91	-0.91	-0.89	-0.61	-0.83	-0.93
Accounts Payable	0.88	0.86	0.92	0.85	0.83	0.74	0.89	0.8	0.61	0.51	-0.9		0.8	0.85	-0.22	0.86	0.79	0.78	0.82	0.11	0.86	0.92	0.89	0.81	0.83	0.86
Cash	0.54	0.8	0.76	0.43	0.49	0.29	0.6	0.79	0.07	0.0	-0.79	0.8		0.5	-0.11	0.74	0.4	0.75	0.87	0.34	0.8	0.69	0.61	0.57	0.49	0.8
Non Current Assets Total	0.74	0.84	0.65	0.82	0.66	0.83	0.79	0.79	0.74	0.78	-0.77	0.85	0.5		0.11	0.68	0.68	0.78	0.47	0.12	0.84	0.69	0.68	0.82	0.66	0.82
Non Currrent Assets Other	-0.57	0.06	-0.56	-0.38	-0.65	-0.2	-0.46	0.14	-0.31	0.23	0.32	-0.22	-0.11	0.11		-0.48	-0.65	0.15	-0.54	0.5	0.06	-0.55	-0.58	-0.04	-0.65	0.02
Other Assets	0.89	0.84	0.95	0.76	0.88	0.56	0.96	0.8	0.5	0.32	-0.97	0.86	0.74	0.68	-0.48		0.83	0.78	0.9	-0.2	0.84	0.94	0.91	0.6	0.88	0.86
Cash And Short Term Investments	0.98	0.55	0.88	0.93	0.98	0.82	0.92	0.46	0.84	0.47	-0.76	0.79	0.4	0.68	-0.65	0.83		0.43	0.72	-0.27	0.55	0.91	0.92	0.68	0.98	0.57
Net Receivables	0.55	0.97	0.66	0.5	0.51	0.38	0.74	0.99	0.25	0.47	-0.88	0.78	0.75	0.78	0.15	0.78	0.43		0.61	0.04	0.97	0.65	0.61	0.53	0.51	0.98
Common Stock Shares Outstanding	0.78	0.72	0.92	0.65	0.76	0.47	0.79	0.68	0.34	0.01	-0.85	0.82	0.87	0.47	-0.54	0.9	0.72	0.61		0.07	0.72	0.86	0.8	0.62	0.76	0.73
Non Current Liabilities Total	-0.2	0.13	-0.15	-0.02	-0.35	0.18	-0.28	0.14	-0.06	-0.18	0.13	0.11	0.34	0.12	0.5	-0.2	-0.27	0.04	0.07		0.13	-0.22	-0.31	0.48	-0.35	0.08
Capital Lease Obligations	0.66	1.0	0.74	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13		0.73	0.68	0.69	0.6	1.0
Other Current Assets	0.96	0.73	0.99	0.85	0.97	0.66	0.96	0.66	0.62	0.42	-0.91	0.92	0.69	0.69	-0.55	0.94	0.91	0.65	0.86	-0.22	0.73		0.99	0.63	0.97	0.75
Other Stockholder Equity	0.96	0.68	0.97	0.83	0.98	0.64	0.96	0.61	0.63	0.44	-0.89	0.89	0.61	0.68	-0.58	0.91	0.92	0.61	0.8	-0.31	0.68	0.99		0.56	0.98	0.7
Total Liab	0.72	0.69	0.63	0.86	0.59	0.91	0.64	0.62	0.76	0.49	-0.61	0.81	0.57	0.82	-0.04	0.6	0.68	0.53	0.62	0.48	0.69	0.63	0.56		0.59	0.66
Net Invested Capital	0.99	0.6	0.94	0.89	1.0	0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.98	0.59		0.62
Property Plant And Equipment Gross	0.67	1.0	0.76	0.64	0.62	0.52	0.82	0.99	0.37	0.46	-0.93	0.86	0.8	0.82	0.02	0.86	0.57	0.98	0.73	0.08	1.0	0.75	0.7	0.66	0.62

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Short Long Term Debt Total	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Liab	4.6M	7.2M	19.6M	23.9M	28.0M	15.3M
Total Current Liabilities	34.6M	110.6M	101.0M	63.3M	85.7M	73.3M
Total Stockholder Equity	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Other Liab	29.6M	77.9M	39.4M	28.2M	32.5M	38.6M
Net Tangible Assets	(74.4M)	283.9M	459.6M	490.2M	563.7M	591.9M
Property Plant And Equipment Net	22.1M	10.8M	11.9M	13.3M	101.1M	106.1M
Current Deferred Revenue	23.3M	170.4M	101.0M	63.3M	37.9M	73.0M
Net Debt	(54.8M)	(13.0M)	(30.0M)	(51.1M)	(25.3M)	(26.6M)
Retained Earnings	(76.5M)	(128.8M)	(229.0M)	(383.8M)	(530.8M)	(504.2M)
Accounts Payable	3.3M	4.4M	4.0M	4.3M	7.1M	4.6M
Cash	76.0M	31.0M	48.0M	68.4M	110.0M	68.7M
Non Current Assets Total	23.9M	184.8M	38.3M	43.6M	170.4M	179.0M
Non Currrent Assets Other	1.8M	11.5M	(98.8M)	(122.0M)	7.9M	8.3M
Other Assets	1.8M	1.6M	8.1M	9.1M	10.5M	11.0M
Cash And Short Term Investments	92.0M	458.7M	567.6M	559.5M	374.9M	383.9M
Net Receivables	287K	1.4M	135K	2.5M	18.8M	19.7M
Common Stock Shares Outstanding	44.5M	17.3M	48.0M	53.9M	58.4M	44.4M
Short Term Investments	15.9M	265.2M	394.4M	338.8M	264.9M	234.5M
Liabilities And Stockholders Equity	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Non Current Liabilities Total	156.5M	92.7M	45.2M	49.7M	95.1M	68.4M
Capital Lease Obligations	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Assets	888K	4.7M	8.7M	9.7M	11.7M	6.6M
Other Stockholder Equity	(107.0M)	412.8M	689.3M	878.9M	926.3M	513.5M
Total Liab	191.1M	203.3M	146.3M	113.0M	180.8M	167.4M
Net Invested Capital	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Property Plant And Equipment Gross	22.1M	20.7M	25.2M	29.1M	111.5M	117.1M
Total Current Assets	92.8M	302.3M	567.6M	559.5M	405.3M	361.1M
Accumulated Other Comprehensive Income	6K	(128K)	(660K)	(4.9M)	(552K)	(579.6K)
Net Working Capital	58.3M	191.7M	358.7M	348.1M	319.6M	240.8M
Short Term Debt	3.4M	6.5M	7.2M	7.9M	12.7M	7.0M
Property Plant Equipment	22.1M	20.7M	11.9M	13.3M	15.3M	15.4M

Pair Trading with Kymera Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Kymera Stock

0.32

KZR

Kezar Life Sciences

Pair Corr

The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.

The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC